IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc (“Reata”), a biopharmaceutical company developing novel drugs for cancer, inflammation and neurodegenerative diseases, today announced the closing of a $25.0 million private financing round. The financing round was led by existing investors, including CPMG, Inc. and Novo A/S.
